Question to the Department of Health and Social Care:

To ask His Majesty's Government what consideration they have given to the impact assessment for the Statutory Scheme for controlling the costs of branded health service medicines, which states that the proposed rebates pose a remote risk to the supply of medicines to the NHS.

The impact assessment published in December 2022 on the impact of proposed changes to payment percentages in the statutory scheme for branded medicines pricing considered matters relevant to the risk to the supply of medicines of any changes.

We have little evidence to suggest that, given the available mitigations, changes to volume-based payment rates will lead to supply issues.

We work closely with suppliers, NHS England, Medicines and Healthcare products Regulatory Agency, the devolved Governments and other stakeholders to ensure patients continue to have access to the treatments they need.